Display options
Cite
Mahesh R, Bhatt S, Devadoss T, et al. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm. 2012;4(4):235-44doi: 10.4103/0975-1483.104367.
Mahesh, R., Bhatt, S., Devadoss, T., Jindal, A., Gautam, B., & Pandey, D. (2012). Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n). Journal of young pharmacists : JYP, 4(4), 235-44. https://doi.org/10.4103/0975-1483.104367
Mahesh, R, et al. "Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n)." Journal of young pharmacists : JYP vol. 4,4 (2012): 235-44. doi: https://doi.org/10.4103/0975-1483.104367
Mahesh R, Bhatt S, Devadoss T, Jindal A, Gautam B, Pandey D. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm. 2012 Oct;4(4):235-44. doi: 10.4103/0975-1483.104367. PMID: 23493308; PMCID: PMC3573375.
Copy Download .nbib Format: NLM
Share it on

J Young Pharm. 2012 Oct;4(4):235-44. doi: 10.4103/0975-1483.104367.

Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n).

Journal of young pharmacists : JYP

R Mahesh, S Bhatt, T Devadoss, Ak Jindal, Bk Gautam, Dk Pandey

Affiliations

  1. Department of Pharmacy, FD-III, Birla Institute of Technology and Science, Pilani, Rajasthan, India.

PMID: 23493308 PMCID: PMC3573375 DOI: 10.4103/0975-1483.104367

Abstract

The present study was designed to evaluate the antidepressant potential of 5-HT3 receptor antagonist N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). The compound '6n' with optimum log P and pA 2 value identified from a series of compounds synthesized in our laboratory was subjected to forced Swim Test (FST) (1, 2, and 4 mg/kg, i.p) and Tail Suspension Test (TST) (1, 2, and 4 mg/kg, i.p.). The compound '6n' significantly reduced the duration of immobility in mice without affecting the baseline locomotion. Moreover, '6n' (2 mg/kg, i.p.) potentiated the 5-hydroxytryptophan (5-HTP)-induced head twitch responses in mice and '6n' at tested dose (1 and 2 mg/kg, i.p.) reversed the reserpine-induced hypothermia in rats. In interaction studies of '6n' with various standard drugs/ligands using FST, '6n' (1 mg/kg, i.p.) potentiated the antidepressant effect of venlafaxine (4 and 8 mg/kg, i.p.) and fluoxetine (10 and 20 mg/kg, i.p.). Additionally, '6n' (1 and 2 mg/kg, i.p.) influenced the effect of harmane (5 mg/ kg, i.p.) as well as reversed the effect of parthenolide (1 mg/kg, i.p.) by reducing the duration of immobility in FST. Furthermore, '6n' (1 mg/kg, i.p.) potentiated the effect of bupropion (10 and 20 mg/kg, i.p.) in TST. Chronic '6n' (1 and 2 mg/kg, i.p.) treatment attenuated the behavioral abnormalities in olfactory bulbectomized rats. In conclusion, these various findings reiterated the antidepressant-like effects of '6n' in behavioral models of depression.

Keywords: 5-HT3 receptor antagonists; forced swim test; head twitch; reserpine; tail suspension test

References

  1. J Pharm Pharmacol. 1978 May;30(5):312-3 - PubMed
  2. Eur J Pharmacol. 2003 Feb 7;461(1):19-25 - PubMed
  3. Arch Int Pharmacodyn Ther. 1965 Nov;158(1):212-21 - PubMed
  4. Psychosom Med. 2005 May-Jun;67 Suppl 1:S26-8 - PubMed
  5. Behav Brain Res. 2005 Nov 7;164(2):266-9 - PubMed
  6. Pharmazie. 2005 Feb;60(2):83-96 - PubMed
  7. Behav Brain Res. 2011 Sep 12;222(1):106-16 - PubMed
  8. J Psychopharmacol. 2010 Apr;24(4):455-69 - PubMed
  9. J Med Chem. 1990 Jun;33(6):1594-600 - PubMed
  10. Scand J Rheumatol Suppl. 2000;113:37-45 - PubMed
  11. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5179-81 - PubMed
  12. Behav Pharmacol. 1997 Nov;8(6-7):523-32 - PubMed
  13. Psychopharmacology (Berl). 1986;90(2):284-5 - PubMed
  14. J Nat Prod. 1992 Aug;55(8):1044-56 - PubMed
  15. Neuron. 2002 Mar 28;34(1):13-25 - PubMed
  16. Mol Pharmacol. 2002 May;61(5):953-63 - PubMed
  17. Pharmacol Ther. 1997;74(3):299-316 - PubMed
  18. J Neurochem. 1993 Feb;60(2):730-7 - PubMed
  19. J Neurochem. 1989 Dec;53(6):1787-93 - PubMed
  20. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(5):735-48 - PubMed
  21. Am J Psychiatry. 2004 Feb;161(2):195-216 - PubMed
  22. Br J Pharmacol. 1973 Oct;49(2):243-52 - PubMed
  23. Behav Brain Res. 2003 Aug 14;143(2):193-200 - PubMed
  24. Psychopharmacology (Berl). 1985;85(3):367-70 - PubMed
  25. J Affect Disord. 2006 May;92(1):79-90 - PubMed
  26. Psychopharmacology (Berl). 1992;109(4):497-8 - PubMed
  27. J Physiol. 1968 Jan;194(1):13-33 - PubMed
  28. Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36 - PubMed
  29. Scand J Rheumatol Suppl. 2000;113:55-8 - PubMed
  30. Nat Med. 2001 May;7(5):541-7 - PubMed
  31. Scand J Rheumatol Suppl. 2004;119:12-8 - PubMed
  32. Fundam Clin Pharmacol. 1990;4(1):49-64 - PubMed
  33. Pharmacol Rep. 2010 Mar-Apr;62(2):245-57 - PubMed

Publication Types